Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative condition in which initiating evidence-based pharmacological treatment promptly at the time of diagnosis is central to current clinical guidelines.
This protocol applies to all people presenting with a new diagnosis of ALS. Guidelines recommend riluzole for all such individuals at diagnosis — the complete structured regimen, including dosing guidance and full management details, is available in the protocol below.